BridgeBio Pharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2836 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Oct 7th, 2026 8:37 am
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting - Oct 6th, 2026 2:01 pm
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 - Oct 6th, 2026 2:01 pm
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day - Oct 6th, 2026 10:57 am
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Oct 6th, 2026 5:30 am
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels - Oct 5th, 2026 5:30 am
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential - Sep 30th, 2026 1:32 pm
The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis - Sep 27th, 2026 5:10 pm
BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands - Sep 27th, 2026 8:07 am
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status - Sep 26th, 2026 2:02 am
Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence - Sep 25th, 2026 2:20 pm
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening - Sep 23rd, 2026 5:47 am
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 18th, 2026 2:01 pm
BioMarin Stops Voxzogo Development for Noonan Syndrome - Sep 16th, 2026 10:01 am
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? - Sep 9th, 2026 9:30 am
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial - Sep 9th, 2026 2:00 am
BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis? - Sep 4th, 2026 10:18 am
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset - Sep 3rd, 2026 10:28 am
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President - Sep 2nd, 2026 4:00 pm